|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of an SYT-SSX gene fusion resulting from the t(X;18) characteristic of synovial sarcoma was demonstrated by reverse transcriptase polymerase chain reaction in three of three tumors in which adequate RNA could be obtained from paraffin blocks.
|
10935649 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Overall survival was significantly better among SYT-SSX2 cases (P = 0.03), among cases localized at diagnosis (P < 0.0001), and among patients with primary tumors < 5 cm in greatest dimension (P = 0.01).
|
11782370 |
2002 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
With this method, 27 tumors (9 synovial sarcomas and 18 nonsynovial sarcomas) were studied and showed SYT-SSX1 rearrangement in 6 cases and SYT-SSX2 in 3 cases.
|
15747098 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As one of the first sarcomas to be defined by the presence of a specific chromosomal translocation leading to the production of the SS18-SSX fusion oncogene, it is perhaps the archetypal "translocation-associated sarcoma," and its translocation remains unique to this tumor type.
|
25438927 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The finding of the SYT-SSX2 translocation is generally associated with a better prognosis, besides tumor negative margins after excision offer the possibility of a better outlook for this patient.
|
16226798 |
2006 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of the t(X;18) with SSX2 involvement definitively characterizes this tumour as a variant of synovial sarcoma.
|
11207827 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hierarchical clustering grouped TMA immunostaining data and confirmed immunophenotypic variability; however, it failed to reveal any immunophenotypic differences between SYT-SSX1 and SYT-SSX2 type tumors.
|
16957934 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This case report indicates that synovial sarcoma should be taken into account for the differential diagnosis of renal spindle cell tumors and the molecular assay detecting the SYT-SSX fusion transcripts is useful for the final diagnosis of synovial sarcoma arising in an unusual location.
|
11422798 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Molecular detection of the SYT-SSX chimeric RNA should allow the reclassification of difficult cases in which the morphologic features overlap different entities or in which tumor nosology is still evolving.
|
9556426 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The SYT-SSX1 and SYT-SSX2 fusion transcripts were detected in 29 (64 percent) and 16 (36 percent) of the tumors, respectively.
|
9428816 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oncogenic SS18-SSX family fusion genes are known to alter the composition of the BAF chromatin-remodeling complex, causing ejection and degradation of wild-type SS18 and the tumor suppressor SMARCB1.
|
29038346 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because SS18/SSX fusions do not seem to occur in other tumor types, and because synovial sarcomas may sometimes be difficult to distinguish from other spindle cell tumors, molecular genetic analysis has become established as an important diagnostic tool.
|
12696068 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On the other hand, the SYT-SSX2 fusion has a weaker de-repression effect on the E-cadherin promoter than does SYT-SSX1, so it is difficult for SYT-SSX2-expressing tumors to achieve sufficient capacity for epithelial differentiation to form glandular structures.
|
24228088 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In view of the specific expression pattern and immunogenicity in cancer patients, HOM-MEL-40 holds promise as a target for immune interventions in a considerable population of patients with HOM-MEL-40-positive tumors.
|
8840996 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These circumstances accentuate the impact of SS18/SSX analysis in diagnosis of renal hemangiopericytoma-like tumors.
|
15163009 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining cytogenetic complexity and transcript data, we found that the subgroup of patients with tumors showing simple karyotypes and SYT/SSX2 fusion had the best clinical outcome (2/8 patients developed metastases), and those with tumors showing complex karyotypes together with SYT/SSX1 fusion the worst (6/7 patients developed metastases).
|
11433527 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This has important implications in understanding the mechanism by which the SYT-SSX fusion protein could contribute to neoplasia.
|
9788446 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the SYT-SSX fusion type is not a significant prognostic factor unlike tumor size, followed by histological grade for patients with localized synovial sarcoma in Japan.
|
18202796 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of 23 SYT-SSX-positive monophasic tumors, 16 tumors had an SYT-SSX1 fusion transcript.
|
9846971 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No correlation was found between CD4+ T-cell responses against p45-59 reactivity and anti-SSX2 antibody titers in the serum of patients, suggesting that CD4+ and B-cell responses are regulated independently. p45-59 holds promise as a broadly applicable peptide vaccine for patients with SSX2-positive neoplasms.
|
15382048 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RT-PCR was used to amplify the SYT-SSX fusion transcripts using archival formalin-fixed paraffin-embedded tumor specimens from a series of 37 synovial sarcoma cases.
|
12150740 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
|
24989082 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The SS18-SSX fusions do not seem to occur in other tumor types, and it has been shown that in synovial sarcoma a clear correlation exists between the type of fusion gene and histologic subtype and, more importantly, clinical outcome.
|
15208645 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SS is characterized by the chromosomal translocation t(X;18)(SYT-SSX) found in more than 95% of the tumors.
|
15725802 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the SYT/SSX2 fusion is usually associated with the monophasic disease pattern, the SYT/SSX1 fusion is present in tumors with biphasic or monophasic patterns.
|
15641030 |
2005 |